Safety of the blood supply: Role of pathogen reduction

Blood Reviews

Volumn 17, Issue 2, 2003, Pages 111-122

  Wu, Yan Yun ^a   Snyder, Edward L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alkylating compounds; Binary ethyleneimine like compounds; Blood supply safety; Methylene blue; Pathogen inactivation; Pathogen reduction; Psoralens; Riboflavin; Solvent detergent treatment

Indexed keywords

PSORALEN; RIBOFLAVIN;

ARTICLE; BACTERIUM CONTAMINATION; BLOOD COMPONENT THERAPY; BLOOD CULTURE; BLOOD TRANSFUSION; DISEASE TRANSMISSION; DNA DAMAGE; HUMAN; HUMAN CELL; LIPID MEMBRANE; PATHOGENESIS; PRIORITY JOURNAL; SAFETY; THROMBOCYTE TRANSFUSION; VASCULARIZATION; VIRUS REPLICATION; VIRUS TRANSMISSION;

EID: 0037409146     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-960X(02)00063-2     Document Type: Article

References (124)

1. AABB. http://www.aabborg/All-About_Blood/FAQs/aabb_faqshtm#6 2002.
2. Ortolano GA, Carmen R, Chong C et al. Cost-effective bacteria detection of platelet concentrate afforded by measuring oxygen in air over eukaryotic cell-filtered, bacteria-laden, plasma. Transfus Clin Biol 2001; 8(Suppl. 1): 31S.
3. Brecher ME, Hay SN, Rothenberg S. Monitoring of apheresis platelet bacterial contamination with the BacT/Alert *3D-A university experience. Transfusion 2002; 42(Suppl): 11S.
4. Stephenson J. Investigation probes risk of contracting West Nile virus via blood transfusions. JAMA 2002; 288(13): 1573-1574.
5. Knight J. Blood banks call for calm over virus scare. Nature 2002; 419(6903): 102.
6. Anonymous. West Nile virus activity - United States, September 19-25, 2002, and Michigan, January 1-September 24, 2002. MMWR - Morbidity Mortality Weekly Rep 2002; 51(38): 862-864.
7. Corash L. Current research perspectives. Transf Med Rev 1999; 13: 18-30.
8. Barbara J. The rationale for pathogen inactivation treatment of platelet components - Introduction. Sem Hematol 2001; 38(4 Suppl. 11): 1-3.
9. Snyder EL, Dodd RY. Reducing the risk of blood transfusion. In: Schecuter GP, Broudy VC, Williams ME, eds. Haematology 2001 American Society of Hematology Education Program Book. American Society of Haematology; 2001. p. 433-442.
10. Council of Europe Expert Committee in Blood Transfusion Study Group on Pathogen Inactivation of Labile Blood Components. Pathogen inactivation of labile blood products. Transfus Med 2001; 11(3): 149-175.
11. Wollowitz S. Fundamentals of the psoralen-based Helinx technology for inactivation of infectious pathogens and leukocytes in platelets and plasma. Sem Hematol 2001; 38(4 Suppl. 11): 4-11.
12. Cook D, Stassinopoulos A, Merritt J et al. Inactivation of pathogens in packed red blood cell (PRBC) concentrates using S-303. Blood 1997; 90(Suppl. 1): 409a.
13. Corash L. Inactivation of viruses, bacteria, protozoa and leukocytes in platelet and red cell concentrates. Vox Sanguinis 2000; 78(Suppl. 2): 205-210.
14. Corash L. Helinx technology for inactivation of infectious pathogens and leukocytes in labile blood components: from theory to clinical application. Transfus Apheresis Sci 2001; 25(3): 179-181.
15. Alfonso R, Lin C, Dupuis K et al. Inactivation of viruses with preservation of coagulation function in fresh frozen plasma. Blood 1996; 88(10 Suppl. 1): 526a.
16. Wages D, Smith D, Walsh J et al. Transfusion of therapeutic doses of virally inactivated fresh frozen plasma in healthy subjects. Blood 1997; 90(10 Suppl. 1): 409a.
17. Wages D, Radu-Radurescu L, Adams M et al. Quantitative analysis of coagulation factors in response to transfusion of S-59 photochemically treated fresh frozen plasma (S-59 FFP) and standard FFP. Blood 1998; 92(Suppl. 1): 503a.
18. Lin L, Cook DN, Wiesehahn GP et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion 1997; 37(4): 423-435.
19. Margolis-Nunno H, Bardossy L, Robinson R, Ben-Hur E, Horowitz B, Blajchman MA. Psoralen-mediated photodecontamination of platelet concentrates: inactivation of cell-free and cell-associated forms of human immunodeficiency virus and assessment of platelet function in vivo. Transfusion 1997; 37(9): 889-895.
20. Lin L, Corten L, Murthy KK, Corash L, Alter HJ. Photochemical inactivation of Hepatitis B (HBV) and Hepatitis C (HCV) virus in human platelet concentrates as assessed by a chimpanzee infectivity model. Blood 1998; 92(10 Suppl. 1): 502a.
21. van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sanguinis 2000; 79(4): 206-214.
22. Wages D, Hambleton J, Viele M et al. RBCs treated with Helinx pathogen inactivation show comparable recovery and survival to standard RBCs in a randomized crossover trial. Blood 2001; 98(Suppl. 1): 449a.
23. Corten L, Dupuis K, Wiesehahn G, Cimino G. Sensitivity of hepatitis C virus to treatment with a novel psoralen and UVA in human platelet. Blood 1996; 88(Suppl. 1): 526a.
24. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology. Sem Hematol 2001; 38(4 Suppl. 11): 27-33.
25. Corten L, Wiesehahn G, Smyers J, Murthy KK, McClure HM, Alter H. Photochemical inactivation of hepatitis B (HBV) and hepatitis C (HCV) viruses in human plasma as assessed in a chimpanzee infectivity model. Blood 2000; 96(11): 60a.
26. Van Voorhis W, Barrett L, Eastman R et al. Helinx technology inactivates Trypanosoma cruzi in human platelet concentrates. Transfusion 2001; 41 (Suppl): 88S.
27. Savoor A, Dikeman R, Lin C, Londe H, Lin L. The S-59 photochemical treatment process for platelet concentrates is robust. Transfusion 1998; 38(10): S29.
28. Lukehart S, Molini B, Dupuis K et al. Inact vation of Treponema pallidum in human platelet concentrates b) Helinx technology. In: Presented at The 7th Annual Meeting of The European Congress of the International Society of Blood Transfusion (ISBT), Paris, France 2001.
29. Belanger KJ, Kelly DJ, Mettille FC, Hanson CV, Lippert LE. Psoralen photochemical inactivation of Orientia tsutsugamushi in platelet concentrates. Transfusion 2000; 40(12): 1503-1507.
30. Dupuis K, Alfonso R, Labaied M, Grellier P. The INTERCEPT blood system for platelets inactivates Plasmodium falciparum. Transfusion 2002; 42(Suppl.): 93S.
31. Savoor A, Mababangloob R, Kinsey J, Dupuis K, Lin L. The INTERCEPT blood system for platelets inactivates anaerobic bacteria. Transfusion 2002; 42(Suppl.): 92S.
32. Hillyer KL, Kelley VA, Roush KS et al. Von Willebrand factor-cleaving protease (vWF-CP) activity in S-59-treated donor plasma. Blood 2001; 98(Suppl. 1): 539a.
33. Pinkoski L, Amir S, Smyers J, Corash L, Ramies D, Wiesehahn G. Photochemically treated INTERCEPT plasma retains protein C, protein S, and antithrombin activities. In: Presented at The 7th Annual Meeting of The European Congress of the International Society of Blood Transfusion (ISBT), Paris, France 2001.
34. Pinkoski L, Smyers J, Corash L, Ramies D, Wiesehahn G. Pathogen inactivation of plasma using Helinx technology conserves the activity of coagulation, anticoagulation, and fibrinolytic proteins. Blood 2001; 98(11): 541a.
35. Pinkoski L, Corash L, Ramies D, Smyers J, Wiesehahn G. The INTERCEPT plasma system: helinx pathogen inactivation technology does not activate thrombin, complement, or the contact system of coagulation. Vox Sanguinis 2002; 83(Suppl. 2): 192.
36. Mintz PD, Avery NL, Monlaison SL et al. Preparation of cryoprecipitate from photochemically treated fresh frozen plasma. Transfusion 2000; 40(Suppl.): 63S.
37. Lin C, Bardossy L, Drerup J, Lin L, Blajchman M. Demonstration of the in vivo hemostatic efficacy of human PCT platelets using a thrombocytopenic rabbit bleeding time model. Vox Sanguinis 2000; 78(Suppl. 1): 0098.
38. Stassinopoulos A, Mababangloob RS, Dupuis K. Bacterial inactivation in leukoreduced PRBC treated with Helinx. Transfusion 2000; 40(Suppl.): 38S.
39. Cook D, Stassinopoulos A, Wollowitz S et al. In vivo analysis of packed red blood cells treated with S-303 to inactivate pathogens. Blood 1998; 92(Suppl. 1): 503a.
40. Kjemtrup AM, Conrad PA, Loui C, Packham A, Stassinopoulos A. Inactivation of Babesia microti in human RBC by Helinx technology. In: Presented at The 7th Annual Meeting of The European Congress of the International Society of Blood Transfusion (ISBT), Paris, France 2001.
41. Schott MA, Kemper M, MacKenzie M, Stassinopoulos A. Helinx pathogen inactivation treatment does not alter INTERCEPT RBC antigen expression and recognition. Blood 2001; 98(11): 110b.
42. Weiskopf RB, Takahashi M, Schott MA et al. Helinx technology for pathogen inactivation does not alter stability of erythrocytes exposed to extracorporeal devices. Vox Sanguinis 2002; 83(Suppl. 2): 119.
43. Hambleton J, Wages D, Radu-Radulescu L et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion 2002; 42(42): 1302-1307.
44. Wages D, Bass N, Keefe E et al. Treatment of acquired coagulopathy by transfusion of fresh frozen plasma (FFP) prepared using a novel, single unit photochemical pathogen inactivation (PI) process. Blood 1999; 94(Suppl. 1): 247a.
45. de Alarcon P, Benjamin R, Shopnick R et al. Hemostatic response in congenital coagulation factor-deficient patients transfused with fresh frozen plasma (FFP) prepared by Helinx pathogen inactivation technology - the STEP CC trial. Transfusion 2001; 41 (Suppl.): 89S.
46. Mintz P, Steadman R, Blackall D et al. Pathogen inactivated fresh frozen plasma prepared using Helinx technology is efficacious and well tolerated in the treatment of end-stage liver disease patients - the STEP AC trial. Blood 2001; 98(Suppl. 1): 709a.
47. Ramies D, Benjamin RJ, Wages D, Valentine ME, Ziomek T, Corash L. The STEP trials demonstrate the safety of INTERCEPT treated fresh frozen plasma. Vox Sanguinis 2002; 83(Suppl. 2): 353.
48. Corash L, Behrman M, Rheinschmidt M et al. Post-transfusion viability and tolerability of photochemically treated platelet concentrates (PC). Blood 1997; 90(Suppl. 1): 267a.
49. Lin L, Behrman B, Rheinschmidt M et al. Photochemically treated platelet concentrates (PC). Jpn J Transfus Med 1998; 44: 178.
50. van Rhenen D, Gulliksson H, Pamphilon D et al. Helinx - photochemically treated platelets are safe and effective for support of thrombocytopenia: results of the Eurosprite Phase 3 trial. Blood 2000; 96(Suppl. 1): 819a.
51. Slichter S. INTERCEPT platelets provide effective hemostasis and count increments: comparison to conventional platelets in two Phase III clinical trials. In: Presented at the 7th Annual Congress of the European Hematology Association (EHA), Florence, Italy 2002.
52. Kluter H, Chapuis B, Cazenave JP et al. Apheresis platelets treated with the INTERCEPT blood system for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets. Vox Sanguinis 2002; 83(Suppl. 2): 110.
53. Conlan M. INTERCEPT platelets (pathogen inactivated platelets using Helinx technology) are hemostatically equivalent to conventional platelets in thrombocytopenic patients: the SPRINT trial. In: Presented at the 23rd Annual Meeting of the American Society for Apheresis (ASFA) 2002.
54. Murphy S, Slichter S, McCullough J et al. INTERCEPT platelets are hemostatically as effective as conventional platelets in the prophylaxis and treatment of bleeding: results of the SPRINT trial. Vox Sanguinis 2002; 83(Suppl. 2): 109.
55. McCullough J, Vesole D, Benjamin R et al. Pathogen inactivated platelets (plt) using Helinx technology (Intercept plt) are hemostatically effective in thrombocytopenic patients (tcp pts): the SPRINT trial. Blood 2001; 98(Suppl.): 450a.
56. Sintnicolaas K, van Rhenen D, Cazenave JP et al. Clinical refractoriness and HLA alloimmunisation are infrequent after multiple exposures to INTERCEPT platelets. In: Presented at the 7th Annual Meeting of The European Congress of the International Society of Blood Transfusion (ISBT), Paris, France 2001.
57. Greenwalt TJ, Hambleton J, Wages D et al. Viability of red blood cells treated with a novel pathogen inactivation system. Transfusion 1999; 39(Suppl. 1): 109S.
58. Hambleton J, Greenwalt T, Viele M et al. Post transfusion recovery after multiple exposures to red blood cell concentrates (RBCs) treated with a novel pathogen inactivation (PI) process. Blood 1999; 94(10): 376a.
59. Rios J, Hambleton J, Viele M et al. Helinx treated RBC transfusion are well tolerated and show comparable recovery and survival to control RBCs. Transfusion 2001; 41 (Suppl.): 38S.
60. Ciaravino V, McCullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001; 20(10): 533-550.
61. Ciaravino V. Preclinical safety of a nucleic acid-targeted Helinx compound: a clinical perspective. Sem Hematol 2001; 38(4 Suppl. 11): 12-19.
62. Ciaravino V, McCullough J. Absence of clinically relevant toxicity in the preclinical safety assessment of INTERCEPT platelets. Blood 2001; 98(11): 540a.
63. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery Jr CA, Butel JS, Bradley A. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1995; 356: 215-221.
64. Ciaravino V, Sullivan T, McCullough T. INTERCEPT-treated platelets and plasma are not carcinogenic in a sensitive transgenic p53 mouse model. Vox Sanguinis 2002; 83(Suppl. 2): 110.
65. Chapman J. Progress in improving the pathogen safety of red cell concentrates. Vox Sanguinis 2000; 78(Suppl. 2): 203-204.
66. Bahnemann H. Binary ethylenimine as an inactivant for foot-and-mouth disease virus and its application for vaccine production. Arch Virol 1975; 47(1): 47-56.
67. AuBuchon JP, Pickard CA, Herschel LH et al. Production of pathogen-inactivated RBC concentrates using PEN110 chemistry: a Phase I clinical study. Transfusion 2002; 42(2): 146-152.
68. Purmal A, Valeri CR, Dzik W et al. Process for the preparation of pathogen-inactivated RBC concentrates by using PEN110 chemistry: preclinical studies. Transfusion 2002; 42(2): 139-145.
69. Lazo A, Tassello J. Viral inactivation of UI cell-associated HIV in red blood cell concentrates by inactine. Transfusion 2000; 40(Suppl.): 38S.
70. Ohagen A, Gibaia V, Aytay S, Xiaochuan Z, Horrigan J, Lazo A. Clinical HIV isolates: a relevant and reproducible model for HIV inactivation studies. In: Presented at the Paul Ehrlich Institute Meeting 2001.
71. Lazo A, Jenks H, Lunderville D, Marmorato A, Billa-Shaveet D, Tassello J. Collection system equivalence using the Inactine process for pathogen inactivation: viral inactivation assessment. Transfusior 2001; 41(Suppl.): 87S.
72. Ohagen A, Gibaja V, Aytay S, Horrigan J, Lunderville D, Lazo A. Inactivation of HIV in blood. Transfusion 2002; 42(10): 1308-1317.
73. Lazo A, Tassello J, Aytay S et al. Inactivation of non-enveloped viruses in red blood cell concentrates using the Inactine compound PEN110. Blood 2001; 98(11 Suppl. 1): 540a.
74. Zavizion B, Serebryanik D, Purmal A. Collection system equivalency using the Inactine process for pathogen inactivation: bacterial inactivation assessment. Transfusion 2001; 41(Suppl.): 89S.
75. Pereira M, Serebryanik D, Purmal A, Jorge M, Zavizion B. Inactivation of virulent Trypanosoma cruzi trypomastigotes by the inactine process. Transfusion 2001; 41(Suppl.): 87S.
76. Zavizion B, Jorge MM, Pereira MA et al. The Inactine PEN110 chemistry eradicates the parasites that cause chagas' disease, malaria, and babesiosis. Vox Sanguinis 2002; 83(Suppl. 2): 118.
77. Hope J, Roth N, Hatigi L et al. High efficiency removal of prion proteins from red cell concentrates by the Inactine process. Blood 2001; 98(11 Suppl.): 542a.
78. Purmal A, Zavizion B, Serebryanik D et al. Removal of white blood cell and plasma proteins from leukofiltered red blood cell concentrates by Inactine pathogen inactivation process. Transfusion 2001; 41 (Suppl.): 90S.
79. Snyder E, Mintz P, Burks S et al. Pathogen inactivated red blood cells using Inactine technology demonstrate 24 h post transfusion recovery equal to untreated red cells after 42 days of storage. Blood 2001; 98(Suppl. 1): 709a.
80. Chapman J, Keys D. Lack of toxicity of PEN110 treated red blood cells without PEN110 removal in New Zealand white rabbits. Transfusion 2001; 41(Suppl): 89S.
81. Chapman J, Fisher B, Moore K. The viral inactivation compound inactine PEN110 lacks reproductive toxicity in rabbits. Vox Sanguinis 2002; 83(Suppl. 2): 191.
82. Chapman J, Moore K, Lyng A, Butterworth BE, Purmal A. Genetic toxicology profile of INACTINE PEN110. Presented in Society of Toxicology Meeting 2002.
83. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sanguinis 2000; 78(Suppl. 2): 211-215.
84. Schuyler R. Use of riboflavin for photoinactivation of pathogens in blood components. Transfus Aphersis Sci 2001; 25: 189-190.
85. McAteer M, Tay-Goodrich B, Doane S, Hansen E, McBurney LL, Stewart L. Photoactivation of virus in packed red cell units using riboflavin and visible light. Transfusion 2000; 40(Suppl.): 99S.
86. Samar BM, Goodrich RP, Services V. Viral inactivation in plasma using riboflavin-based technology. Transfusion 2001; 41(Suppl.): 88S.
87. Reddy H, Doane S, McLean S, McDaniel S, Dawson L. Riboflavin and visible light inactivate HIV IIIB and hepatitis C analog (BVDV) in RBC. Vox Sanguinis 2002; 83(Suppl. 2): 119.
88. Lippert LE, Watson R, Doane S, Reddy H, Goodrich L. Inactivation of P. falciparum by riboflavin and light. Vox Sanguinis 2002; 83(Suppl. 2): 163.
89. McBurney LL, Goodrich TB, Hansen ET. The use of riboflavin for the viral inactivation of platelets. Transfusion 2000; 40(Suppl.): 37S.
90. Tay-Goodrich B, Schuyler R, Goodrich R, Dumont L. Evaluation of in vivo survival of photochemically treated platelet concentrates in non-human primates. Transfusion 2000; 40(Suppl.): 38S.
91. Goodrich L, Hansen E, Gampp D, Woolum M. Riboflavin pathogen inactivation process yields good platelet cell quality and expedient viral kill. Blood 2001; 98(11 Suppl. 1): 540a.
92. Goodrich L, Ghielli M, Hansen E et al. Riboflavin and UV light inactivate enveloped and non-enveloped viruses in platelet concentrates under conditions which maintain cell quality. Vox Sanguinis 2002; 83(Suppl. 2): 111.
93. Palavecino EL, Jacobs MR, Goodrich RP, McBurney LL, Goodrich TB, Yomtovian RA. Photochemical decontamination of bacteria: analysis of log and stationary growth phases. Transfusion 2001; 41 (Suppl.): 88S.
94. De Korte D, Gouwerok E, Vlaar R, Van Engelenburg F, McBurney LL, Verhoeven AJ. In vitro storage characteristics of platelets in the presence of riboflavin. Transfusion 2001; 41(Suppl.): 88S.
95. Goodrich RP, Hansen E, Zavorskas P. In vivo tolerance of photochemically treated platelets using riboflavin and light. Transfusion 2001; 41 (Suppl.): 38S.
96. Burtis CA, Ashwood ER, eds. Tietz fundamentals of clinical chemistry. Philadelphia: W.B. Saunders, 1996.
97. Piper J, Schuyler R, Haynes R, Wilson A. Evaluation of acute toxicity and genotoxicity risks associated with the riboflavin photoproduct lumichrome. Transfusion 2001; 41 (Suppl.): 90S.
98. Wagner SJ, Skripchenko A, Robinette D, Mallory DA, Cincotta L. Preservation of red cell properties after virucidal phototreatment with dimethylmethylene blue. Transfusion 1998; 38(8): 729-737.
99. Wagner SJ, Skripchenko A, Pugh JC, Suchmann DB, Ijaz MK. Duck hepatitis B photoinactivation by dimethylmethylene blue in RBC suspensions. Transfusion 2001; 41(9): 1154-1158.
100. Skripchenko A, Wagner S. Identification of the target responsible for M13 virus inactivation by dimethylmethylene blue and light treatment. Transfusion 2000; 40(Suppl.): 37S.
101. Skripchenko A, Wagner S. Inactivation of WBCs in RBC suspensions by photoactive phenothiazine dyes: comparison of dimethylmethylene blue and MB. Transfusion 2000; 40: 968-975.
102. Wagner SJ, Skripchenko A, Thompson-Montgomery D. Quinacrine enhances vesicular stomatis virus (VSV) inactivation and diminishes hemolysis of dimethylmethylene blue (DMMB) phototreated cells. Transfusion 2002; 42(Suppl.): 94S.
103. Pehta JC. Clinical studies with solvent detergent-treated products. Transfus Med Rev 1996; 10(4): 303-311.
104. Morgenthaler JJ. New developments in plasma fractionation and virus inactivation. Vox Sanguinis 2000; 78(Suppl. 2): 217-221.
105. Klein HG, Dodd RY, Dzik WH et al. Current status of solvent/detergent-treated frozen plasma. Transfusion 1998; 38(1): 102-107.
106. Product circular for Pooled plasma, solvent/detergent treated. VI Technologies 2002.
107. Grass JA, Hei DJ, Metchette K et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998; 91(6): 2180-2188.
108. Hei DJ, Grass J, Lin L, Corash L, Cimino G. Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light. Transfusion 1999; 39(3): 239-248.
109. Fast LD, DiLeone G, Edson CM, Purmal A. PEN110 treatment functionally inactivates the PBMNCs present in RBC units: comparison to the effects of exposure to γ irradiation. Transfusion 2002; 42(10): 1318-1325.
110. Corash L, Grass J, Hei D, Wages D. Prevention of platelet TA-GVHD by photochemical treatment. Jpn J Transfus Med 1998; 44: 178.
111. Talib S, Truitt RL, Johnson BD et al. Use of S-59 UVA treated leukocytes for allogeneic cellular immune therapy (ACIT). Blood 1999; 94(10): 320a.
112. Truitt R, Johnson B, Hanke C, Talib S, Hearst J. Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. J Immunol 1999; 163(9): 5145-5156.
113. Fast LD, DiLeone G, Edson CM, Purmal A. Inhibition of murine GVHD by PEN110 treatment. Transfusion 2002; 42(10): 1326-1332.
114. Grass JA, Wafa T, Reames A et al. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999; 93(9): 3140-3147.
115. Hanson D, Propst M, Dupuis K, Schott MA, Stassinopoulos A, Johnson KM. High titer leukocyte inactivation in INTERCEPT red blood cells (RBC). In: Presented at The 7th Annual Meeting of The European Congress of the International Society of Blood Transfusion (ISBT), Paris, France 2001.
116. Grass J, Delmonte J, Wages D, Lin L, Ferrara J, Corash L. Prevention of transfusion associated graft vs. host disease (TA-GVHD) in immunocompromised mice by photochemical treatment (PCT) of donor T cells. Blood 1997; 90(S1): 207a.
117. Luban NL. Prevention of transfusion-associated graft-versus-host disease by inactivation of T cells in platelet components. Sem Hematol 2001; 38(4 Suppl. 11): 34-45.
118. Liu W, Hanchett J, Ng M et al. A potential application of photochemically treated CliniMACS CD34(-) fraction for allogeneic cellular immune therapy. In: Presented at the 7th Annual Meeting of the International Society for Hematotherapy & Graft Engineering (ISHAGE), Quebec City, Quebec, Canada 2001.
119. Hearst JE, Reames A, Grass J, Talib S. S-59/UVA treated human T-Cells with precisely controlled genomic addition frequencies retain immunological functions and yet are inhibited in proliferation. Blood 1998; 92:S1: 292b.
120. Truitt R, Johnson B, Rosenblum M, Talib S. Allogeneic cellular immunotherapy by S-59/Uva-treated donor leukocytes in mice with T-depleted BMT. Blood 1998; 92: 436a.
121. Gajewski JL, Devine SM, DiPersio J, Talib S. Helinx treated T-cells as an adjunct to T-cell depleted mismatched haploidentical PBSC transplantation. Blood 2001; 98(11): 670a.
122. Ng M, Liu W, Hanchett JD, Hearst JE. Helinx-treated peripheral blood mononuclear cells (PBMC) with amotosalen hydrochloride maintain their biological functions post-cryopreservation. Blood 2001; 98(11): 332b.
123. Reames A, Falahati R, Liu W, Hearst JE. Helinx-treated peripheral blood mononuclear cells facilitate the graft-versus-leukemia effect during allogeneic stem cell transplantation. Blood 2001; 98(11): 327b.
124. Fast L, Edson C, DiLeone G. PEN110 treatment is more effective than conventional γ irradiation at inhibiting human peripheral blood mononuclear cell function: in vitro studies. Transfusion 2001; 41 (Suppl.): 39S.